Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585481 | 1.00 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL203128 | 1.00 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL22330742 | 1.00 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL13192453 | 1.00 | SLC5A2 (0.79) | SLC5A2SLC5A1 | |
| SCHEMBL13278337 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL152222 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL17627816 | 0.87 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL223808 | 0.87 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL148029 | 0.87 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL9975451 | 0.87 | SLC5A2 (0.78) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214471-A | Novel compound | MITSUBISHI TANABE PHARMA CORP | 2013-07-24 | — | — | CN | claimed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | claimed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | claimed |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-14 | — | — | US | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2455374-B1 | Process for the Preparation of Compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-28 | — | — | US | disclosed |
| US-20190194177-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 | JANSSEN PHARAMCEUTICA NV (BE) | 2019-06-27 | — | — | US | disclosed |
| EP-2451482-B1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-01 | — | — | EP | disclosed |
| EP-2200606-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Janssen Pharmaceutica, N.V. (BE) | 2010-06-30 | — | — | EP | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010043682-A2 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2009035969-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| CN-1829729-A | Novel compounds | TANABE SEIYAKU CO (JP) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | SLC5A2 472/4885SLC5A1 303/4885 |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885 |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | SLC5A2, SLC5A1, SI | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20190194177-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 | SLC5A2, SLC5A1, SI | SLC5A2 1/4885SLC5A1 2/4885 |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.